- Home
- TGTX vs ARW Comparison
TGTX vs ARW Comparison
Compare TGTX & ARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- ARW
- Stock Information
- Founded
- TGTX 1993
- ARW 1935
- Country
- TGTX United States
- ARW United States
- Employees
- TGTX N/A
- ARW N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- ARW Electronic Components
- Sector
- TGTX Health Care
- ARW Technology
- Exchange
- TGTX Nasdaq
- ARW Nasdaq
- Market Cap
- TGTX 5.5B
- ARW 5.8B
- IPO Year
- TGTX 1995
- ARW N/A
- Fundamental
- Price
- TGTX $33.20
- ARW $108.01
- Analyst Decision
- TGTX Strong Buy
- ARW Sell
- Analyst Count
- TGTX 4
- ARW 2
- Target Price
- TGTX $54.75
- ARW $102.00
- AVG Volume (30 Days)
- TGTX 2.2M
- ARW 689.2K
- Earning Date
- TGTX 11-03-2025
- ARW 10-30-2025
- Dividend Yield
- TGTX N/A
- ARW N/A
- EPS Growth
- TGTX N/A
- ARW 0.79
- EPS
- TGTX 2.78
- ARW 9.05
- Revenue
- TGTX $531,898,000.00
- ARW $29,389,382,000.00
- Revenue This Year
- TGTX $82.31
- ARW $9.85
- Revenue Next Year
- TGTX $49.05
- ARW $5.17
- P/E Ratio
- TGTX $11.98
- ARW $11.93
- Revenue Growth
- TGTX 100.88
- ARW 3.16
- 52 Week Low
- TGTX $25.28
- ARW $86.50
- 52 Week High
- TGTX $46.48
- ARW $134.74
- Technical
- Relative Strength Index (RSI)
- TGTX 55.65
- ARW 42.87
- Support Level
- TGTX $30.15
- ARW $101.79
- Resistance Level
- TGTX $33.79
- ARW $108.74
- Average True Range (ATR)
- TGTX 1.18
- ARW 2.51
- MACD
- TGTX 0.29
- ARW 0.36
- Stochastic Oscillator
- TGTX 87.33
- ARW 54.23
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About ARW Arrow Electronics Inc.
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.